Fifty-two week follow-up safety and effectiveness results of dupilumab treatment of moderate-to-severe atopic dermatitis from a retrospective, multicentric series
| Autor: | Leandro Martinez-Pilar, José Juan Pereyra-Rodríguez, Ricardo Ruiz-Villaverde, Sara Alcantara-Luna, J.C. Armario-Hita, Javier Domínguez-Cruz |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male Moderate to severe Systemic disease medicine.medical_specialty Dermatology Dupilumab Antibodies Monoclonal Humanized Severity of Illness Index Dermatitis Atopic Young Adult 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Immune system Humans Medicine media_common.cataloged_instance In patient European union Retrospective Studies media_common Atopic dermatitis business.industry General Medicine Middle Aged medicine.disease Treatment Outcome Spain 030220 oncology & carcinogenesis Etiology Female business Follow-Up Studies |
| Zdroj: | Digital.CSIC. Repositorio Institucional del CSIC instname |
| Popis: | Atopic dermatitis (AD) is a chronic, systemic disease that has a multifactorial etiology, where immune system disorders and epidermal barrier dysfunction are added to the influence of genetic and environmental factors. Dupilumab has been approved by United States and the European Union regulatory agencies in 2017 for the treatment of moderate-to-severe AD in adult patients who are candidates for systemic treatment. In this short report, we present a retrospective, multicentric study, in which five hospitals in Andalusia, Spain, have taken part. Our objective is to evaluate the safety and effectiveness of dupilumab in patients with moderate-to-severe AD treated with dupilumab with at least 52 weeks of follow-up. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|